In conclusion, these results demonstrate that risk scores calculated based on SLC2A3 and ASNS can effectively classify the COAD cohort into high-risk and low-risk groups, enabling the assessment of survival prognosis in COAD patients. This evidence concerns the gene SLC2A3 and colon adenocarcinoma.